Compare Novavax Inc (NVAX) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Tidewater Inc — how do they compare? Novavax Inc trades at $12.64 (market cap $1.82B), while Tidewater Inc trades at $85.05 (market cap $4.21B). The key difference: Tidewater Inc is far larger — about 2.3× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Tidewater Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Tidewater Inc for 25 Days on average.
| NVAX | TDW | |
|---|---|---|
Market Cap | $1.82B | $4.21B |
Volume | 6,198,505 | 590,005 |
Sector | Health | Energy |
52-Week High | $12.56 | $100.61 |
52-Week Low | $6.22 | $47.29 |
Typical Hold Time | 59 Days | 25 Days |
Enterprise Value | $1.39B | $4.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Tidewater (TDW) trades at $85.16, up 2.11% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with an 18.34% net margin and 19.49% ROE, though recent earnings missed expectations in Q1 and Q2 2026. The company completed the Wilson Sons Ultratug acquisition in August 2026, enhancing its offshore services footprint. Cash flow remains robust with $252.54M net cash flow in 2025.
Outlook is mixed: analyst consensus targets $105.50 (23.9% upside), but earnings volatility and competitive pressures pose risks. Institutional interest is strong, with BlackRock investing $503.20M in Q2 2026. Investors should weigh solid fundamentals against execution risks in a volatile energy market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
